Cingulate to Present at 13th Annual LD Micro Invitational
26 May 2023 - 5:55AM
Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company
utilizing its proprietary Precision Timed Release™ (PTR™) drug
delivery platform technology to build and advance a pipeline of
next-generation pharmaceutical products, today announced it will
participate in the 13th Annual LD Micro Invitational at the Luxe
Sunset Boulevard Hotel, Los Angeles, California, on June 6th-8th,
2023. The event is expected to feature 150+ companies, presenting
in half-hour increments, as well as private one-on-one meetings.
Cingulate Chairman & CEO Shane J. Schaffer
is scheduled to present a company overview on June 6th at 9:30 a.m.
PST. A webcast of the presentation will be available on the
investors section of Cingulate’s corporate site at
www.cingulate.com.
Cingulate’s lead Phase 3 candidate, CTx-1301, is
a novel, investigational treatment being developed as a true,
once-daily stimulant medication for attention deficit/hyperactivity
disorder (ADHD). In addition to the Company’s initial focus on the
$22bn ADHD market, Cingulate is identifying other indications, such
as anxiety, where it’s PTR™ technology may be effectively
utilized.
To arrange a meeting with Cingulate, please
contact your LD Micro representative, or Cingulate investor
relations at mkreps@darrowir.com.
About Cingulate®Cingulate Inc. (NASDAQ: CING),
is a clinical-stage biopharmaceutical company utilizing its
proprietary PTR™ drug delivery platform technology to build and
advance a pipeline of next-generation pharmaceutical products,
designed to improve the lives of patients suffering from frequently
diagnosed conditions characterized by burdensome daily dosing
regimens and suboptimal treatment outcomes. With an initial focus
on the treatment of neurological disorders, Cingulate is
identifying and evaluating additional therapeutic areas where PTR™
technology may be employed to develop future product candidates,
including to treat anxiety disorders. Cingulate is headquartered in
Kansas City. For more information visit Cingulate.com.
Investor Contact:Thomas DaltonVice President,
Investor & Public Relations,
Cingulate913-942-2301TDalton@cingulate.com
Matt KrepsDarrow Associates Investor
Relations214-597-8200mkreps@darrowir.com
Cingulate (NASDAQ:CINGW)
Historical Stock Chart
From Apr 2024 to May 2024
Cingulate (NASDAQ:CINGW)
Historical Stock Chart
From May 2023 to May 2024